PURPOSE: The purpose of this study was to evaluate the efficacy and tolerability of continuous low-dose cyclophosphamide and prednisone (CP) as a salvage therapy for multiple myeloma (MM). PATIENTS AND METHODS: A total of 27 consecutive patients with MM received a treatment regimen that consisted of oral cyclophosphamide 50 mg and prednisone 15 mg daily. Nineteen patients had severe comorbid conditions; 8 were unwilling to continue conventional chemotherapy as a result of severe infection associated with the conventional chemotherapy. Patients had received 1 to 4 chemotherapeutic regimens before the enrollment. RESULTS: The overall response rate (complete remission, very good partial response, and partial response) was 66.7%. The median time to response was 2 months. In the patients who responded to the treatment, the median progression-free survival (PFS) has not been reached. In the nonresponding patients, the median PFS was 4 months. CONCLUSION: Continuous low-dose CP is an effective and well-tolerated salvage therapy for MM.
PURPOSE: The purpose of this study was to evaluate the efficacy and tolerability of continuous low-dose cyclophosphamide and prednisone (CP) as a salvage therapy for multiple myeloma (MM). PATIENTS AND METHODS: A total of 27 consecutive patients with MM received a treatment regimen that consisted of oral cyclophosphamide 50 mg and prednisone 15 mg daily. Nineteen patients had severe comorbid conditions; 8 were unwilling to continue conventional chemotherapy as a result of severe infection associated with the conventional chemotherapy. Patients had received 1 to 4 chemotherapeutic regimens before the enrollment. RESULTS: The overall response rate (complete remission, very good partial response, and partial response) was 66.7%. The median time to response was 2 months. In the patients who responded to the treatment, the median progression-free survival (PFS) has not been reached. In the nonresponding patients, the median PFS was 4 months. CONCLUSION: Continuous low-dose CP is an effective and well-tolerated salvage therapy for MM.
Authors: Christina A To; Robert W Hsieh; James Scott McClellan; Walter Howard; Nancy J Fischbein; Janice M Y Brown; Dean W Felsher; Alice C Fan Journal: BMJ Case Rep Date: 2012-09-07
Authors: R Hájek; T Masszi; M T Petrucci; A Palumbo; L Rosiñol; A Nagler; K L Yong; A Oriol; J Minarik; L Pour; M A Dimopoulos; V Maisnar; D Rossi; H Kasparu; J Van Droogenbroeck; D B Yehuda; I Hardan; M Jenner; M Calbecka; M Dávid; J de la Rubia; J Drach; Z Gasztonyi; S Górnik; X Leleu; M Munder; M Offidani; N Zojer; K Rajangam; Y-L Chang; J F San-Miguel; H Ludwig Journal: Leukemia Date: 2016-06-24 Impact factor: 11.528